A case of pyoderma gangrenosum with ulcerative colitis treated with combined approach: Infliximab and surgery | Zendy

G. Andrisani | Zendy; Luisa Guidi | Zendy; Angela Papa | Zendy; A.E. Potenza | Zendy; Daniele Cervelli | Zendy; A. Armuzzi | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

A case of pyoderma gangrenosum with ulcerative colitis treated with combined approach: Infliximab and surgery

Author(s) -

G. Andrisani,

Luisa Guidi,

Angela Papa,

A.E. Potenza,

Daniele Cervelli,

A. Armuzzi

Publication year - 2012

Publication title -

journal of crohn s and colitis

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.277

H-Index - 80

eISSN - 1876-4479

pISSN - 1873-9946

DOI - 10.1016/j.crohns.2012.07.021

Subject(s) - pyoderma gangrenosum , infliximab , ulcerative colitis , medicine , pathogenesis , inflammatory bowel disease , monoclonal , monoclonal antibody , dermatology , disease , tumor necrosis factor alpha , immunology , antibody

Pyoderma gangrenosum (PG) is an ulcerating noninfectious disease of the skin seen in 1-2% of patients with inflammatory bowel disease (IBD). The pathogenesis of PG has yet to be determined, but may be related to abnormal T cell responses and the production of TNF-α, a pathway also involved in IBD pathogenesis. Infliximab, a chimeric monoclonal antibody to TNF-α, is used to treat moderate to severe IBD and several case reports and studies suggest the efficacy of infliximab in the treatment of PG. The surgical approach to PG is reserved to a few selected cases. We report here the case of a patient with ulcerative colitis (UC) and PG localized on the left breast, treated with a simultaneous combined medical and surgical approach.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research